Trials
Search / Trial NCT06436612

Study of Magnetic Resonance Image and Computed Tomography-Guided Stereotactic Body Radiation Therapy for Abdominopelvic Sarcomas (MARS Trial)

Launched by JONSSON COMPREHENSIVE CANCER CENTER · May 28, 2024

Trial Information

Current as of February 08, 2025

Recruiting

Keywords

ClinConnect Summary

The MARS Trial is a clinical study focused on improving radiation treatment for patients with abdominopelvic sarcomas, a type of cancer that occurs in the abdomen or pelvis. The researchers aim to use advanced imaging techniques, specifically MRI, to deliver targeted radiation therapy. This method helps ensure that the radiation hits the tumor accurately while protecting nearby vital organs. Participants in the study will receive radiation treatment every day for five days, followed by surgery to remove the tumor within 12 weeks after finishing radiation. The medical team will continue to monitor the participants for five years to assess their health and recovery.

To be eligible for this study, participants must be at least 12 years old and have a confirmed diagnosis of sarcoma that can be treated surgically. They should have a good performance status, meaning they can carry out daily activities with minimal difficulty. It’s important to note that individuals with other active cancers or those who have previously received radiation therapy in the same area may not be able to participate. If you or a loved one is interested, the study is currently recruiting participants and the team is ready to provide more information about the process and what to expect.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Histologically confirmed sarcoma
  • Primary or recurrent disease involving the abdomen or pelvis
  • Resectable primary lesion
  • Age ≥ 12 years old
  • Karnofsky performance status (KPS) ≥ 70 or Eastern Cooperative Oncology Group (ECOG) 0-2
  • If a woman is of childbearing potential, a negative serum or urine pregnancy test must be documented
  • Exclusion Criteria:
  • Active treatment of a separate malignancy
  • History of prior irradiation to the area targeted for treatment

About Jonsson Comprehensive Cancer Center

The Jonsson Comprehensive Cancer Center (JCCC) is a leading research and treatment institution dedicated to advancing cancer prevention, diagnosis, and treatment through innovative clinical trials and cutting-edge research. Affiliated with the University of California, Los Angeles (UCLA), the JCCC integrates a multidisciplinary approach, bringing together experts in oncology, genetics, and public health to foster collaboration and translate scientific discoveries into effective therapies. With a commitment to improving patient outcomes and quality of life, the JCCC conducts a wide range of clinical trials aimed at addressing various cancer types, ensuring that patients have access to the most advanced therapeutic options available.

Locations

Los Angeles, California, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0